Nefazodone withdrawal

June 2004
Reactions Weekly;6/12/2004, Issue 1005, p10
Discusses research being done on the side effects of the abrupt discontinuation of the drug nefazodone on a patient diagnosed with depression. Reference to a study by L. Tamam and N. Ozpoyraz, published in the December 2003 issue of the "Journal of Psychopharmacology"; Drug dosage administered to the patient; Length of drug use; Central nervous system disorders developed by the patient.


Related Articles

  • Amisulpride.  // Reactions Weekly;9/18/2004, Issue 1019, p6 

    Discusses research being done on the side effects of amisulpride in an elderly patient with chronic paranoid schizophrenia. Reference to a study by K. Jagadheesan and D. Muirhead published in the July 2004 issue of the "Australian and New Zealand Journal of Psychiatry"; Occurrence of...

  • Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues. Winston, A.; Moecklinghoff, C.; Hill, A. // International Journal of STD & AIDS;Mar2012, Vol. 23 Issue 3, p225 

    A letter to the editor is presented which discusses the assessment of the rates of central nervous system (CNS) adverse events and cognitive function within three years under the MONET study of ritonavir and darunavir.

  • Efavirenz-associated CNS disorders linked to CYP2B6 variant.  // Reactions Weekly;1/22/2005, Issue 1035, p5 

    Discusses research being done on the pharmacogenetics of efavirenz and central nervous system (CNS) side effects. Reference to a study by D. W. Haas et al published in the December 3, 2004 issue of "AIDS"; Differences in efavirenz clearance and susceptibility to efavirenz-associated adverse CNS...

  • Acomplia ADRs reported to MHRA.  // Reactions Weekly;5/17/2008, Issue 1202, p2 

    The article discusses a study on adverse drug reactions (ADRs) associated with Accomplia or ricombinant. It references a study published in the May 2008 issue of the "Drug Safety Update." Accoridng to the study, 1,971 individual reactions related to the drug have been reported. It is noted that...

  • Cladribine.  // Reactions Weekly;12/15/2012, Issue 1432, p17 

    The article describes the case of a 57-year-old man who developed central nervous system (CNS) tuberculosis following the administration of a single course of cladribine for hairy cell leukemia.

  • CNS News Round-Up.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p17 

    The article offers news briefs on the development of drugs for the treatment of central nervous system diseases. ReNeuron has received funding from the Michael J. Fox Foundation for a new type of Parkinson's disease treatment, ReN004, that has the potential to reverse the neurological effects of...

  • REUTERS: HEALTH INFORMATION.  // Neurology Reviews;Mar2008, Vol. 16 Issue 3, p18 

    The article offers several neurological disease-related studies in the U.S. in 2008. A phase II trial has determined that high-dose of methotrexate is an effective treatment for primary central nervous system lymphoma. Research has found out that intravenous immunoglobulin (IVIg) is helpful in...

  • Reversible central nervous system dysfunction due to tamoxifen in a patient with breast cancer. Pluss, Jerry L.; DiBella, Nicholas J.; Pluss, J L; DiBella, N J // Annals of Internal Medicine;Nov84, Vol. 101 Issue 5, p652 

    Presents a case study of a breast cancer patient who developed reversible central nervous system dysfunction due to tamoxifen. Medical history of the patient; Results of physical and laboratory examinations; Outcome of treatment.

  • Phenytoin interaction.  // Reactions Weekly;8/26/2006, Issue 1116, p22 

    The article describes the case of a 25-year-old man who developed benign angiopathy of the central nervous system (CNS) during concomitant treatment with clobazam while receiving phenytoin for epilepsy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics